Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IN10018 + pegylated liposomal doxorubicin
- Development stage
- Unknown
- Lead developer
- InxMed
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
**IN10018 + pegylated liposomal doxorubicin** is a combination regimen consisting of IN10018, a highly potent and selective small molecule inhibitor of focal adhesion kinase (FAK), and pegylated liposomal doxorubicin (PLD), an anthracycline chemotherapy encapsulated in pegylated liposomes. IN10018 inhibits FAK—an intracellular tyrosine kinase that plays a role in tumor progression and fibrotic barrier formation—and is intended to synergize with PLD, potentially overcoming platinum resistance and improving antitumor effects in ovarian cancer. PLD works by blocking topoisomerase 2, inhibiting cancer cell division, and being delivered via liposomes prolongs bloodstream residence and enhances tumor targeting. The combination is specifically under investigation for platinum-resistant ovarian cancer.
- Brand names
- Caelyx
- Other names
- pegylated liposomal doxorubicinPLDIN10018IN-10018IN 10018
02
Targets
DNAFAK (Focal adhesion kinase)
Beyond the preview
Go deeper on IN10018 + pegylated liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IN10018 + pegylated liposomal doxorubicin.